Evidence map›Paper›PMID 33921230›Full record

ArticleInternational journal of molecular sciences2021

Selective Anti-Cancer Effects of Plasma-Activated Medium and Its High Efficacy with Cisplatin on Hepatocellular Carcinoma with Cancer Stem Cell Characteristics.

Yan Li, Tianyu Tang, Hae June Lee, Kiwon Song

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Yan LiDepartment of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.
Tianyu TangDepartment of Electrical Engineering, Pusan National University, Busan 46241, Korea.
Hae June LeeDepartment of Electrical Engineering, Pusan National University, Busan 46241, Korea.ORCID 0000-0003-3401-3355
Kiwon SongDepartment of Biochemistry, College of Life Science and Biotechnology, Yonsei University, Seoul 03722, Korea.
Pusan National University · KRYonsei University · KR

Funding

National Research Foundation of Korea NRF2020R1A2C1102153The Bio & Medical Technology Development Program of NRF Korea NRF2016M3A9C6918275
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a major histological subtype of primary liver cancer. Ample evidence suggests that the pathological properties of HCC originate from hepatic cancer stem cells (CSCs), which are responsible for carcinogenesis, recurrence, and drug resistance. Cold atmospheric-pressure plasma (CAP) and plasma-activated medium (PAM) induce apoptosis in cancer cells and represent novel and powerful anti-cancer agents. This study aimed to determine the anti-cancer effect of CAP and PAM in HCC cell lines with CSC characteristics. We showed that the air-based CAP and PAM selectively induced cell death in Hep3B and Huh7 cells with CSC characteristics, but not in the normal liver cell line, MIHA. We observed both caspase-dependent and -independent cell death in the PAM-treated HCC cell lines. Moreover, we determined whether combinatorial PAM therapy with various anti-cancer agents have an additive effect on cell death in Huh7. We found that PAM highly increased the efficacy of the chemotherapeutic agent, cisplatin, while enhanced the anti-cancer effect of doxorubicin and the targeted-therapy drugs, trametinib and sorafenib to a lesser extent. These findings support the application of CAP and PAM as anti-cancer agents to induce selective cell death in cancers containing CSCs, suggesting that the combinatorial use of PAM and some specific anti-cancer agents is complemented mechanistically.

Indexed as

Plasma GasesAntineoplastic Combined Chemotherapy ProtocolsApoptosisCarcinogenesisCarcinoma, HepatocellularCell LineCell Line, TumorCell ProliferationCisplatinCulture MediaDoxorubicinHumansLiverLiver NeoplasmsNeoplastic Stem CellsCisplatinCulture MediaDoxorubicinPlasma Gasescaspase-dependent and -independent cell deathcold atmospheric-pressure plasma (CAP)combinatorial therapyhepatocellular carcinoma cell lines Hep3B and Huh7 with cancer stem cell populationsplasma-activated medium (PAM)

Identifiers

PMID33921230
PMCPMC8069277
OpenAlexW3155661962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.